High-dose Cytarabine Therapy Research Articles

Comparison of the Prophylactic Effects of 2-Deoxycytidine and Prednisolone for High-Dose Intravenous Cytarabine-Induced Keratitis

In a double-masked, randomized fashion, 11 patients with hematologic malignancies received 13 courses of high-dose cytarabine therapy, intravenously (3 g/m2 every 12 hours for five to six days). Each patient received topical prednisolone phosphate 1% in one eye and 2-deoxycytidine 100 microM in the other eye every six hours. Topical therapy was initiated 12 hours before the first cytarabine dose and continued for up to ten days (until four to five days after completion of cytarabine therapy). Slit-lamp biomicroscopy was performed before therapy and then weekly for one month. 2-Deoxycytidine was equally as effective as the topical corticosteroid therapy in reducing photophobia and pain, microcysts, and punctate epithelial erosions, and each treatment gave results significantly better when compared historically to placebo-treated eyes.

Pericarditis induced by high-dose cytarabine therapy

Pericarditis induced by high-dose cytarabine therapy

Pericarditis Induced by High-Dose Cytarabine Therapy

Pericarditis with tamponade developed in a patient treated with high-dose cytarabine for acute lymphocytic leukemia. Evidence suggests that this was a direct complication of his treatment.